Cookson Peirce & Co’s CRISPR Therapeutics CRSP Stock Holding History

Cookson Peirce & Co’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-6,215	Closed	-$389K	–	230
2023 Q4	$389K	Buy	+6,215	New	+$344K	0.02%	166
2022 Q3	–	Sell	-17,783	Closed	-$1.08M	–	192
2022 Q2	$1.08M	Buy	+17,783	New	+$1.05M	0.07%	100
2021 Q4	–	Sell	-15,053	Closed	-$1.69M	–	211
2021 Q3	$1.69M	Buy	15,053 +1,726	+13%	+$217K	0.1%	101
2021 Q2	$2.16M	Buy	+13,327	New	+$1.62M	0.13%	95
2021 Q1	–	Sell	-17,183	Closed	-$2.63M	–	180
2020 Q4	$2.63M	Buy	17,183 +1,539	+10%	+$182K	0.18%	70
2020 Q3	$1.31M	Buy	15,644 +4,446	+40%	+$394K	0.1%	83
2020 Q2	$823K	Buy	11,198 +1,652	+17%	+$96.6K	0.08%	81
2020 Q1	$405K	Buy	+9,546	New	+$493K	0.05%	105
2019 Q3	–	Sell	-8,105	Closed	-$382K	–	139
2019 Q2	$382K	Buy	+8,105	New	+$324K	0.03%	129
2019 Q1	–	Sell	-7,620	Closed	-$218K	–	147
2018 Q4	$218K	Buy	+7,620	New	+$265K	0.02%	144

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cookson Peirce & Co's CRSP Position: Q1 2024 in Review

Cookson Peirce & Co sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 6,215 shares — an estimated $389K sold.

Cookson Peirce & Co first reported a position in CRSP in Q4 2018 and held it in 10 quarters. The position peaked at $2.63M in Q4 2020. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

Cookson Peirce & Co reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
Cookson Peirce & Co sold 6,215 CRISPR Therapeutics shares in Q1 2024, an estimated $389K.
Cookson Peirce & Co first reported a position in CRISPR Therapeutics in Q4 2018 and held it in 10 quarters.
Cookson Peirce & Co's CRISPR Therapeutics position peaked at $2.63M in Q4 2020.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Cookson Peirce & Co's 13F filing for Q1 2024, filed 23 Apr 2024.